Variable | Biomarker | Reference | Association | Sample Size, HC, PsA, PsC | Spearman Rho, r | 95% CI | p | Units for Serum Concentration |
---|---|---|---|---|---|---|---|---|
VDH composite score | ||||||||
M-CSF | Dalbeth 2010 | Yes | 12, 38, 10 | < 0.01 | pg/ml | |||
RANKL | Dalbeth 2010 | Yes | 12, 38, 10 | < 0.05 | pmol/l | |||
DKK-1 | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
OPG | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
Joint space narrowing | ||||||||
RANKL | Dalbeth 2010 | Yes | 12, 38, 10 | < 0.05 | pmol/l | |||
M-CSF | Dalbeth 2010 | Yes | 12, 38, 10 | < 0.01 | pg/ml | |||
DKK-1 | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
OPG | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
Peripheral erosions | M-CSF | Dalbeth 2010 | Yes | 12, 38, 10 | Charted | < 0.001 | pg/ml | |
MMP-3 | Chandran 2010 | No | 26, 26, 26 | NS | ng/ml | |||
DKK-1 | Dalbeth 2010 | No | 12, 38, 10 | Charted | > 0.05 | pg/ml | ||
RANKL | Chandran 2010 | No | 26, 26, 26 | NS | pg/l | |||
RANKL | Dalbeth 2010 | No | 12, 38, 10 | Charted | > 0.05 | pmol/l | ||
OPG | Chandran 2010 | No | 26, 26, 26 | NS | pg/ml | |||
OPG | Dalbeth 2010 | No | 12, 38, 10 | Charted | > 0.05 | pg/ml | ||
COMP | Chandran 2010 | No | 26, 26, 26 | NS | ng/ml | |||
C2C | Chandran 2010 | No | 26, 26, 26 | NS | ng/ml | |||
C1-2C | Chandran 2010 | No | 26, 26, 26 | NS | mcg/ml | |||
CPII | Chandran 2010 | No | 26, 26, 26 | NS | Ratio | |||
Osteolysis | RANKL | Dalbeth 2010 | Yes | 12, 38, 10 | < 0.05 | pmol/l | ||
M-CSF | Dalbeth 2010 | Yes | 12, 38, 10 | < 0.05 | pg/ml | |||
DKK-1 | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
OPG | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
Osteoproliferation | DKK-1 | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | ||
RANKL | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pmol/l | |||
M-CSF | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
OPG | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
Sacroiliitis | MMP-3 | Chandran 2010 | No | 26, 26, 26 | NS | ng/ml | ||
RANKL | Chandran 2010 | No | 26, 26, 26 | NS | pg/l | |||
RANKL | Dalbeth 2010 | Uncertain | 12, 38, 10 | NS | pmol/l | |||
OPG | Chandran 2010 | No | 26, 26, 26 | NS | pg/ml | |||
OPG | Dalbeth 2010 | Uncertain | 12, 38, 10 | NS | pg/ml | |||
BMP-2 | Grcevic 2010 | No | 25, 23, 0 | NS | NS | |||
BMP-4 | Grcevic 2010 | No | 25, 23, 0 | NS | NS | |||
BMP-6 | Grcevic 2010 | No | 25, 23, 0 | NS | NS | |||
COMP | Chandran 2010 | No | 26, 26, 26 | NS | ng/ml | |||
C2C | Chandran 2010 | No | 26, 26, 26 | NS | ng/ml | |||
C1-2C | Chandran 2010 | No | 26, 26, 26 | NS | mcg/ml | |||
CPII | Chandran 2010 | No | 26, 26, 26 | NS | Ratio | |||
DKK-1 | Dalbeth 2010 | Uncertain | 12, 38, 10 | NS | pg/ml | |||
M-CSF | Dalbeth 2010 | Uncertain | 12, 38, 10 | NS | pg/ml | |||
BMD hip | DKK-1 | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | ||
RANKL | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pmol/l | |||
M-CSF | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
OPG | Dalbeth 2010 | No | 12, 38, 10 | > 0.05 | pg/ml | |||
BMD lumbar spine | OPG | Hofbauer 2006 | No | 90, 116, 0 | 0.046 | 0.62 | pmol/l | |
TRAIL | Hofbauer 2006 | No | 90, 116, 0 | 0.142 | 0.13 | pg/ml | ||
BMD femur | OPG | Hofbauer 2006 | No | 90, 116, 0 | 0.033 | 0.72 | pmol/l | |
TRAIL | Hofbauer 2006 | No | 90, 116, 0 | 0.089 | 0.34 | pg/ml |
HC: healthy control; PsA: psoriatic arthritis; PsC: cutaneous psoriasis without arthritis; VDH: van der Heijde score for PsA; M-CSF: macrophage colony-stimulating factor; RANKL: receptor activator of nuclear factor-κB ligand; DKK-1: Dickkopf-1; OPG: osteoprotegerin; MMP-3: matrix metalloproteinase-3; COMP: cartilage oligomeric matrix protein; BMP: bone morphogenetic protein; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand; BMD: bone mineral density; NS: not stated; C1-2C: a neoepitope released when type 2 cartilage is degraded by collagenases; CPII:C2C: ratio of cartilage degradation vs byproduct formation.